LA JOLLA, California, July 31, 2020 (GLOBE NEWSWIRE) – INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-level immunology corporation aimed at finding remedies that leverage patient innate immune formula to combat disease, announced that it will make a convention call on August 5, 2020 at 4:30 p.m. Eastern Time to talk about the effects of its quarterly moment on June 30, 2020.
Conference information
To participate in this event, dial between five and 10 minutes before the call starts. Request the call from the quarter INmune Bio convention at the time an operator taps.
Date: August 5, 2020 Time: 4:30 p.m. Eastern Time Participant Call: 212-231-2931
Clinical trials are at an early level and there is no guarantee that express final results will be achieved. All statements contained in this press release that do not describe ancient facts could possibly constitute forward-looking statements that the term is explained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, adding, without limitation, statements regarding the final touch and timing of the offer and the quantity and use of the resulting product are based on existing expectations, but are subject to a number of hazards and insecurities. The actual effects and timing of certain occasions and cases may differ materially from those described in the forward-looking statements as a result of these dangers and insecurities. INB03 ™, XPro1595, LIVNate ™, Quellor ™ and INKmune ™ are still in clinical trials or are preparing to begin clinical trials and have not been approved and it cannot be guaranteed that they will be approved or that the express effects will be achieved. . Our two platforms are starting clinical trials and there is no guarantee of the good luck of those trials. Factors that may also cause real long-term effects to differ materially from existing expectations include, but are not limited to, hazards and insecurities related to the company’s ability to produce more medicines for clinical trials; The availability of a truly extensive additional investment to enable the company to continue its operations and conduct studies and development, clinical studies and marketing of long-term products; and the company’s marketing and distribution activities, studies, product development, regulatory approval, marketing and distribution plans and strategies. These and other points are known and described in more detail in the Company’s filings with the Securities and Exchange Commission, adding the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q, and the Company’s existing Reports on Form 8-K. The Company assumes no legal responsibility to update forward-looking statements to reflect any occasion or circumstance that may occur after the date of this release.
David Moss, CFO (858) [email protected]
Inverter Contact: James Carbonara, Hayden IR (646) [email protected]